Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q1 2025 · 10-Q
Revenue—
Net Income-$6.41M-$6.41MN/M vs Q1 2024 EPS Diluted-$1,581.81-$1,581.81N/M vs Q1 2024 Operating Income-$6,480,000N/M Operating Cash Flow-$6,575,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 15, 2025 · 45 d after period end